All In Biotech

NDA 022159 · Septodont Holding

Oraverse

Phentolamine Mesylate · Injection

Last checked: Nov 20, 2026Latest source record: Mar 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

May 9, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

46

14 Phase 3, 7 recruiting

FAERS reports

112

89 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2018.

1. INDICATONS AND USAGE OraVerse an alpha adrenergic blocker, is indicated for adult and pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse, an alpha adrenergic blocker, is indicated for adult and pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. ( 1 )

Mechanism: The mechanism by which OraVerse accelerates reversal of soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model, OraVerse increased local blood flow in submucosal tissue of the dog when given after an intraoral injection of lidocaine 2% with 1:100,000 epinephrine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORAVERSE · PHENTOLAMINE MESYLATE 0.4MG/1.7ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phentolamine" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood urea increased14
  • blood glucose increased13
  • neutrophil count increased13
  • anaemia12
  • diarrhoea12
  • lymphocyte count decreased12
  • hypertension11
  • dizziness10
  • haemoglobin decreased10
  • abdominal distension9
  • hypoaesthesia9
  • pyrexia9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
20076
20081
20094
20102
201115
20126
20131
20143
20153
20165
201720
20189
20195
20206
20216
20224
20233
20254
20265

Recalls

2 FDA enforcement reports for this application.

  • Oct 31, 2025 · Class II · Ongoing

    Defective container: cracked/broken cartridges

  • Apr 13, 2018 · Class III · Terminated

    Failed Impurities/Degradation: This recall has been initiated due to an out of specification (OOS) result that was obtained for related substance (Phentolamide), a known degradation product impurity at the 15 month...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 275 on PubMed

Sponsor: Septodont Holding

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.